Docetaxel in cationic lipid nanocapsules for enhanced in vivo activity

References

• Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50:S41–S67
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3–19
   PubMed Web of Science ®Google Scholar
• Beig A, Miller JM, Dahan A. Accounting for the solubility–permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm 2012;81:386–391
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119–131
   PubMed Web of Science ®Google Scholar
• Jain AS, Date AA, Nagarsenker MS. Design, characterization and evaluation of anti-epileptic activity of nanoprecipitating preconcentrate of carbamazepine. Drug Deliv Lett 2013;3:61–69
   Google Scholar
• Jain AS, Shah SM, Nagarsenker MS, et al. Lipid colloidal carriers for improvement of anticancer activity of orally delivered quercetin: formulation, characterization and establishing in vitro–in vivo advantage. J Biomed Nanotechnol 2013;9:1230–1240
   PubMed Web of Science ®Google Scholar
• Ahmad J, Kohli K, Mir SR, Amin S. Lipid based nanocarriers for oral delivery of cancer chemotherapeutics: an insight in the intestinal lymphatic transport. Drug Deliv Lett 2013;3:38–46
   Google Scholar
• Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3–16
   PubMed Web of Science ®Google Scholar
• Jain AS, Khachane PV, Shah SM, Nagarsenker MS. Nanoemulsions: a potential delivery system. Pharm Rev 2011:113–119
   Google Scholar
• Yan YD, Kim DH, Sung JH, et al. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 2010;399:116–120
   PubMed Web of Science ®Google Scholar
• ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665–685
   PubMed Web of Science ®Google Scholar
• Lee E, Kim H, Lee IH, Jon S. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 2009;140:79–85
   PubMed Web of Science ®Google Scholar
• Yin YM, Cui FD, Mu CF, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009;140:86–94
   PubMed Web of Science ®Google Scholar
• Malingré MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:1160–1166
   PubMed Web of Science ®Google Scholar
• Rouini MR, Lotfolahi A, Stewart DJ, et al. A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. J Pharm Biomed Anal 1998;17:1243–1247
   PubMed Web of Science ®Google Scholar
• Rao BM, Chakraborty A, Srinivasu MK, et al. A stability-indicating HPLC assay method for docetaxel. J Pharm Biomed Anal 2006;41:676–681
   PubMed Web of Science ®Google Scholar
• Pérez-De La Cruz V, González-Cortés C, Pedraza-Chaverrí J, et al. Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. Brain Res Bull 2006;68:379–383
   PubMed Web of Science ®Google Scholar
• Makhija DT, Jagtap AG. Studies on sensitivity of zebrafish as a model organism for Parkinson's disease-comparison with rat model. J Pharmacol Pharmacother 2014;5:39–46
   PubMedGoogle Scholar
• Goel PN, Gude RP. Curbing the focal adhesion kinase and its associated signalling events by pentoxifylline in MDA-MB-231 human breast cancer cells. Eur J Pharmacol 2013;714:432–441
   PubMed Web of Science ®Google Scholar
• Date AA, Nagarsenker MS, Patere S, et al. Lecithin-based novel cationic nanocarriers (Leciplex) II: Improving therapeutic efficacy of quercetin on oral administration. Mol Pharm 2011;8:716–726
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Bouligand Y, Benoit JP. New lipid nanocapsules exhibit sustained release properties for Amiodarone. J Control Release 2002;84:59–68
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Saumet JL, Roux J, Benoit JP. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int J Pharm 2004;278:407–414
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Benoit JP. The gastrointestinal stability of lipid nanocapsules. Int J Pharm 2009;379:260–265
   PubMed Web of Science ®Google Scholar
• Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 2009;379:201–209
   PubMed Web of Science ®Google Scholar
• Wempe MF, Wright C, Little JL, et al. Inhibiting efflux with novel non-ionic surfactants: rational design based on vitamin E TPGS. Int J Pharm 2009;370:93–102
   PubMed Web of Science ®Google Scholar
• Ren X, Mao X, Cao L, et al. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. Eur J Pharm Sci 2009;36:401–411
   PubMed Web of Science ®Google Scholar
• Kusumoto K, Ishikawa T. Didodecyldimethylammonium bromide (DDAB) induces caspase-mediated apoptosis in human leukemia HL-60 cells. J Control Release 2010;147:246–252
   PubMed Web of Science ®Google Scholar
• Dhawan VV, Joshi G, Jain AS, et al. Apoptosis induction and anti-cancer activity of LeciPlex formulations. Cell Oncol (Dordr) 2014;37:339–51
   PubMed Web of Science ®Google Scholar
• Barros TP, Alderton WK, Reynolds HM, et al. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 2008;154:1400–1413
   PubMed Web of Science ®Google Scholar
• Bayliss PE, Bellavance KL, Whitehead GG, et al. Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. Nat Chem Biol 2006;2:265–273
   PubMed Web of Science ®Google Scholar
• Parng C, Seng WL, Semino C, McGrath P. Zebrafish: a preclinical model for drug screening. Assay Drug Dev Technol 2002;1:41–48
   PubMed Web of Science ®Google Scholar
• Menke AL, Spitsbergen JM, Wolterbeek AP, Woutersen RA. Normal anatomy and histology of the adult zebrafish. Toxicol Pathol 2011;39:759–775
   PubMed Web of Science ®Google Scholar
• Faria M, Navarro A, Luckenbach T, et al. Characterization of the multixenobiotic resistance (MXR) mechanism in embryos and larvae of the zebra mussel (Dreissena polymorpha) and studies on its role in tolerance to single and mixture combinations of toxicants. Aquat Toxicol 2011;101:78–87
   PubMed Web of Science ®Google Scholar
• Sturm A, Segne H. P-glycoproteins and xenobiotic efflux transport in fish (Chapter 18). In: Mommsen TP, Moon TW, eds. Biochemistry and molecular biology of fishes. Amsterdam, the Netherlands: Elsevier B.V.; 2005:495–533
   Google Scholar